Despite medtech investment falling by 30 percent in 2022, a March 27 report from consulting firm Deloitte found that investors remain confident in finding value in the medtech sector.
Investors are turning toward platform-enabled businesses, or businesses that create an ecosystem of users, as the industry struggles with macroeconomic factors such as inflation, interest rate hikes and banking scares.
Deloitte found that eight of the 10 best-funded later-stage medtech companies operated as platform-enabled businesses.
"According to the executives we interviewed, some investors decided to pause new investments or shift to earlier-stage investments to adapt to today's economic climate," the report said. "The shift in focus seems to have resulted in a 'back to basics' approach that may continue into 2023. In addition to focusing on growth, innovators may be looking to achieve stability, to help them bridge longer funding cycles, and, potentially, provide meaningful value to their clients."